The Drug Enforcement Administration has scheduled a hearing on Dec. 2 to consider reclassifying cannabis to a less dangerous drug, with the results of the presidential election impacting the implementation of any potential changes. If the measure passes, the decision will likely be influenced by the outcome of the election, highlighting the significance of the upcoming hearing in relation to drug policy.
Source link
Danaher Beats Q2 Revenue, EPS Forecasts
Global science and technology innovator Danaher (NYSE:DHR) reported Q2 2025 results on July 22, exceeding analysts' expectations with $5.94 billion in revenue and adjusted EPS of $1.80. Despite a decline in net earnings to $555 million, ongoing operational discipline led to an increased full-year adjusted EPS outlook, although challenges persist in Life Sciences and Diagnostics. Want More Context? 🔎
Read more